{"id":"W7132949618","doi":"","title":"Ad-hoc COVID-19 Clinical Pharmacology Task Group Statement on Tocilizumab and Sarilumab. PHAC.","year":2021,"lang":"en","type":"other","venue":"TSpace","topic":"","field":"","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"","keywords":"Statement (logic); Clinical pharmacology; Task (project management); Tocilizumab; Agency (philosophy); Regulatory agency; Alternative medicine; Public health","routes":{"ca_aff":false,"ca_fund":false,"ca_venue":false,"about_ca":true,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.006087536,0.001042348,0.001472724,0.001686275,0.001931281,0.003650681,0.003668002,0.007227989,0.2077413],"category_scores_gemma":[0.01501086,0.0009805934,0.00145681,0.001861458,0.000865103,0.001230699,0.00160492,0.005407398,0.1535148],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.006742447,"about_ca_system_score_gemma":0.03564181,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.09784497,"about_ca_topic_score_gemma":0.2349018,"domain_scores_codex":[0.9944989,0.0009009486,0.0004928892,0.0003732699,0.002811894,0.000922109],"domain_scores_gemma":[0.9840899,0.001763178,0.001169086,0.0005389944,0.00887356,0.003565369],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"not_applicable","study_design_gemma":"not_applicable","study_design_scores_codex":[0.00006572327,0.00002825421,0.00006776436,0.00008376885,0.000004324535,0.00002120824,0.00000524802,0.00002709826,0.00005792613,0.001020392,0.9906824,0.007935948],"study_design_scores_gemma":[0.0001962397,0.00003442077,0.0007342526,0.0002899485,0.00001357702,0.0000582516,0.00001100058,0.00007758756,0.0001179215,0.0006697705,0.9977864,0.0000107213],"study_design_candidate":"not_applicable","study_design_consensus":"not_applicable","genre_codex":"other","genre_gemma":"commentary","genre_scores_codex":[0.0006961593,0.00977846,0.002280256,0.07137883,0.01622713,0.002412363,0.09847617,0.00111091,0.7976398],"genre_scores_gemma":[0.005737897,0.007189386,0.00322117,0.06857654,0.005851123,0.002029511,0.07026052,0.0009354919,0.8361983],"genre_candidate":"commentary","genre_consensus":null,"teacher_disagreement_score":0.2077413,"threshold_uncertainty_score":0.6949638,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.100426416263252,"score_gpt":0.4904741963970279,"score_spread":0.3900477801337759,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}